Umbrella Labs: Historical Record and Current Access
The FDA’s May 18, 2021 Umbrella warning letter identifies umbrella.us and related sites including umbrellalabs.is, with a Tucson address in that historical record. It establishes the entity and domains addressed then, not current corporate continuity or today’s warehouse location. Direct retrieval of umbrellalabs.is was unavailable in this review; no order or logged-in record was inspected.
Product Identity: Catalog Labels Are Not Chemical Classes
FDA’s historical letter describes products marketed as SARMs and other research materials. Those marketing categories are not a correct classification for every named molecule. Ibutamoren (MK-677) is a growth-hormone secretagogue, and Cardarine (GW-501516) is a PPARβ/δ agonist; neither should be called a SARM. This review does not establish the current catalog or any material’s treatment suitability.
Testing and Certificates: What Needs Verification
A vendor-wide claim that every batch has independent identity, purity, sterility or contaminant testing needs the actual reports and sample coverage. No current lot report was independently authenticated for this review. Check the exact material, lot identifier, amount, laboratory, method and date, and distinguish seller posting from issuer verification. A certificate does not automatically establish every quality attribute or clinical safety.
Pricing: No Current Comparative Quote
This review does not establish a current item price, volume discount or competitive market tier. Price comparison requires the same material, form, amount, documentation, date and complete charges. A higher price cannot be justified as a quality premium without evidence of the claimed differences.
Shipping and Delivery: Policy vs. Experience
No current shipping policy, order, packaging, delivery or cold-chain test was completed. A claim of US-based shipping needs current records; a historical FDA address does not establish today’s fulfillment arrangements. Obtain destination-specific written terms and distinguish estimated dispatch from documented delivery.
Reputation: Keep Transactions and Assays Separate
No independently examined customer dataset establishes current service quality, repeat-purchase rates or product consistency here. Reviews should be tied to dates, actual items and transactions. A positive testimonial is not an assay, and a negative account is not by itself proof of a business-wide pattern.
What the Available Record Supports
- A dated FDA record links the named operation and domains to specific marketing and product findings in 2021.
- Chemical identity can be checked independently of a seller’s catalog category.
- A useful supplier assessment separates current entity, lot documentation, price and order performance.
What Remains Unresolved
- Current website retrieval and operator continuity.
- Current catalog, item-specific prices, shipping and return terms.
- Authentication and coverage of any current lot reports.
- Actual fulfillment, support and customer outcomes.
An unresolved question is an evidence limit, not an allegation that a defect, closure or fraud occurred.
Assessment: Regulatory Record, Not a Blanket Vendor Score
FDA’s 2021 letter described unapproved and misbranded drug marketing; research-only wording did not negate the human-use claims the agency cited. A later closeout is not established here. This dated finding does not itself prove current product composition, operation or a whole-vendor quality rating. No purchase recommendation or human-use protocol follows.
Editorial method: this guide synthesizes the linked primary sources and separates program terms from individual eligibility. It does not report firsthand product testing or a clinician review. See our editorial process and corrections contact.